The pivotal Phase 2 trial a 48-week study published in The New England Journal of Medicine in 2023 produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly: Average weight loss of around 24% from baseline A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss Continued weight loss right up to the 48-week endpoint, with no plateau in sight For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks
The FAERS database also revealed 41 reported cases for semaglutide with an ROR of 11.36 (95% CI, 8.33 to 15.49) and a PRR of 11.36 (95% CI, 8.32 to 15.47), suggesting a potential causal relationship between semaglutide and NAION [98]
In large-scale trials, participants using the molecule often saw a substantial percentage of body weight loss when combined with lifestyle changes
Elevated insulin levels also tell your ovaries to produce more testosterone, which can disrupt ovulation, throw off your cycle, and make it harder to get pregnant
.png)
